Literature DB >> 19900144

Para-aortic lymph node metastasis in malignant dysgerminoma of the ovary.

Benjamin Kasenda1, Philipp Harter, Tobias Hirsch, Alexander Ast, Christine Buhrmann, Florian Glaser, Andreas Du Bois.   

Abstract

Dysgerminomas comprise approximately 2-5% of all ovarian malignancies and mostly affect young adolescent women. Primary comprehensive surgery and adjuvant chemotherapy consisting of bleomycin, etoposide, and cisplatin (BEP) are the current recommended treatment options, the latter reserved for advanced stages (FIGO II-IV). We report two patients aged 20 and 26 years who presented with an initial FIGO stage IA, but inadequately assessed. Both were subsequently diagnosed with recurrent malignant dysgerminoma and para-aortic lymph node metastasis. Neither had received comprehensive staging at initial surgery nor adjuvant radio or chemotherapy. Both needed extensive surgery and multiagent chemotherapy for survival and belong to the small percentage of FIGO IA dysgerminoma patients showing a relapse. Comprehensive initial surgery including systematic para-aortic lymphadenectomy and adjuvant chemotherapy at tertiary referral centers is needed to minimize the treatment burden.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900144     DOI: 10.3109/00016340903242461

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

Review 1.  Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.

Authors:  Jin Li; Xiaohua Wu
Journal:  Curr Treat Options Oncol       Date:  2016-08

2.  Ovarian dysgerminoma with a metastasis to para-aortic lymph node.

Authors:  Rieko Kawase; Shunji Suzuki
Journal:  Clin Case Rep       Date:  2021-12-13

Review 3.  Uncommon Metastasis of Ovarian Dysgerminoma: A Case Report and Review of the Literature.

Authors:  Mihaela Camelia Tîrnovanu; Irina Daniela Florea; Adina Tănase; Bogdan Florin Toma; Elena Cojocaru; Carmen Ungureanu; Ludmila Lozneanu
Journal:  Medicina (Kaunas)       Date:  2021-05-27       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.